This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CytRx Announces Research And Development Day And Webcast

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Company will host a Research and Development Day on Friday, May 2, from 8:30 – 11:30 am EDT at the Harvard Club in New York City.

The event, which will be open to analysts and institutional investors, will include presentations by, and a panel discussion with, key opinion leaders in oncology and sarcoma, including the principal investigator for the Company’s pivotal, global Phase 3 trial of aldoxorubicin in patients with soft tissue sarcoma. Breakfast will be served. Please RSVP to maeve@argotpartners.com. CytRx invites the public and the media to join the event via the webcast.

Speakers scheduled to present include:

Daniel Von Hoff, M.D., F.A.C.P.

Dr. Von Hoff currently serves as Physician in Chief and Director of the Translational Genomics Research Institute (TGEN) in Phoenix, Arizona. He is also Chief Scientific Officer for the US Oncology Network, one of the nation’s largest networks of community-based oncology physicians dedicated to advancing cancer care in America. He is currently serving a six-year term on the National Cancer Advisory Board and has served on the FDA's Oncology Advisory Committee. Dr. Von Hoff is a past president of the American Association for Cancer Research, was on the AACR and the American Society of Clinical Oncology's Board of Directors, and is a fellow of the American College of Physicians. He is the founder of Investigational New Drugs - The Journal of New Anticancer Agents and is currently editor-in-chief of Molecular Cancer Therapeutics.

Sant Chawla, M.D., F.R.A.C.P.

Dr. Chawla is the Principal Investigator for the aldoxorubicin global Phase 3 pivotal trial in second-line soft tissue sarcoma. He was the Principal Investigator for the Phase 2b and Phase 1b/2 clinical trials with aldoxorubicin. Dr. Chawla currently serves as Director of Medical Oncology at the UCLA-Santa Monica Hospital, Director of Medical Oncology at Orthopaedic Hospital, and as Director of Medical Oncology at Century City Hospital. Dr. Chawla also currently heads the Sarcoma Oncology Center in Santa Monica, CA. Following completion of his medical degree and residency training at the All India Institute of Medical Sciences in New Delhi, Dr. Chawla completed a fellowship in medical oncology in New Zealand, at the Fellow Royal Australasian College of Physicians (F.R.A.C.P.), and later, in recognition for his outstanding academic accomplishments, he was invited to continue his fellowship in oncology at the prestigious M.D. Anderson Cancer Center of the University of Texas.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,153.82 -374.21 -2.26%
S&P 500 1,929.30 -42.88 -2.17%
NASDAQ 4,687.6020 -88.9060 -1.86%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs